Serum Biomarker Discovery for IBD

A number of serum biomarkers have entered the everyday lab routine to diagnose IBD. These serum biomarkers aren't IBD specific but these are frequently used as an initial diagnostic tool because they're simple to use, inexpensive, and have well-tested protocols. Scientists have conducted large-scale studies of non-invasive serum biomarkers for determining markers that can be used to diagnose, subclassify, track disease activity, and predict treatment and side effects.

Fig. 1. Serum biomarkers for inflammatory bowel disease (IBD) management. Fig. 1. Serum biomarkers for IBD management. (Chen et al., 2020)

Serum Biomarker Discovery Services

Ace Therapeutics is a global provider of IBD research services dedicated to serum biomarker discovery. We utilize advanced technologies (e.g., proteomics techniques, cytokine profiling, high-throughput sequencing technologies) to ensure the accuracy and reliability of results for your exploratory biomarker discovery needs.

Our serum biomarker discovery service can be used to help our clients find biomarkers to monitor disease course, therapy response, and toxicity. Integrating biomarker discovery to IBD drug development will allow novel therapies to be developed faster.

Serum Biomarkers You May Be Interested In

Based on immunological, serological, and genetic assays, we can identify several serum biomarkers of IBD and evaluate the effects of IBD drugs in cellular or animal models. Our goal is to assist clients in discovering novel serum biomarkers that are cost-effective and more accessible.

C-reactive protein (CRP)	Erythrocyte sedimentation rate (ESR)	Leucine-rich alpha-2 glycoprotein (LRG)
Cytokines: IL-1β, IL-6, IL-8, IL-9, IFN-γ, TNF, CCL2, IL-22	Non-coding RNAs (ncRNAs): microRNA (miRNA) and long ncRNA (lncRNA)	Trefoil factor 3 (TFF3)
Galectins	Amyloid A (SAA)	Gelsolin
Extracellular matrix (ECM) components: Fibronectin, laminin, collagen, procollagen III N-terminal propeptide (PIIINP), C-terminal propeptide of type I collagen (PICP), and C-terminal telopeptide of type I collagen (ITCP)	Growth factors: basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), YKL-40	Oncostatin M (OSM)
Serum metabolites: Fatty acid, acylcarnitine metabolite, sphingolipid, and bile acid metabolism	Matrix metalloproteinase (MMP)-1, MMP-2, MMP-3, MMP-9	Angiopoietin-1, angiopoietin-2

What Questions Can You Answer via Our Serum Biomarker Discovery Services?

Our team of scientists supports and assists you in selecting the most effective biomarker strategy for your research needs. We offer serum biomarker services either as part of a comprehensive preclinical project package or as individual analytical solutions. This could include the identification and analysis of biomarkers that inform:

Ensure that your compound acts on-target during the entire IBD drug discovery process starting at hit identification.
Understand the mode of action of the compound.
Find a pharmacodynamic marker to monitor the efficacy of your compound and enabling dosing experiments in animal models of IBD.
Determine the immune-modulating activity of immunotherapeutics.
Identify genetic and/or environmental factors that predispose to IBD or cause IBD progression.
Monitor disease status, the occurrence of new disease effects, and changes in disease severity.

Ace Therapeutics specializes in the extensive examination of biomarkers in serum samples, assisting clients in the identification of biomarkers specific to IBD. Through an advanced biocomputational technique for analyzing multi-omics data, we provide valuable insights that deepen the understanding of IBD mechanisms and support the development of novel therapeutics. If you would like to learn more, please do not hesitate to contact us.

Reference

Chen, P., et al. (2020). Serum biomarkers for inflammatory bowel disease. Frontiers in Medicine, 7, 123.

! For research use only, not intended for any clinical use.